Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.23.3
Income Taxes (Tables)
12 Months Ended
Jun. 30, 2023
Income Taxes [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)

The components of the provision (benefit) for income taxes consist of the following (in thousands):

For the Years Ended

June 30, 

 

2023

 

2022

Current – Federal and state

$

$

Deferred – Federal

    

(12,153)

    

(9,051)

Deferred – State

 

(637)

 

Total

 

(12,790)

 

(9,051)

Change in valuation allowance

 

12,790

 

9,051

Income tax expense

$

$

Schedule of Deferred Tax Assets and Liabilities

The components of the Company’s deferred tax assets and liabilities are as follows (in thousands):

    

As of June 30, 

    

2023

2022

Deferred tax assets (liabilities):

Net operating loss

$

42,951

$

35,829

Share-based compensation

 

883

 

1,248

Capitalized research and development costs

2,775

Research and development tax credits

 

1,764

 

1,764

Investment in equity security

395

370

Property, plant and equipment

121

(2,520)

Intangible assets

 

(42)

 

(71)

Operating and finance lease liabilities

1,363

Operating and finance lease ROU assets

(1,184)

Accrued expenses

 

529

 

145

Valuation allowance

 

(49,555)

 

(36,765)

Total

$

$

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the statutory tax rate to the effective tax rate is as follows:

    

Years Ended

June 30, 

    

2023

2022

Statutory federal income tax rate

 

21

%  

21

%

State taxes, net of federal benefit

 

1

%  

%

Expiration and forfeiture of stock options

(2)

%  

%

Change related to iBio CDMO

 

%  

(3)

%

Change in valuation allowance

 

(20)

%  

(18)

%

Effective income tax rate

 

%  

%